Codexis to Participate in the Cowen 42nd Annual Health Care Conference

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42nd Annual Health Care Conference, being held virtually March 7-9, 2022.

The “Synthetic Biology Enabling Discovery” panel discussion is taking place on Tuesday, March 8, 2022, at 3:30 p.m. ET, and the fireside chat is taking place on Wednesday, March 9, 2022, at 1:30 p.m. ET. Webcasts of both events will be available in the Investor Relations section of the Company’s website, panel presentation and fireside chat webcasts will be archived for 30 and 90 days, respectively, following the event.

About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit

Investor Relations Contact:
Argot Partners
Brendan Strong/Carrie McKim
(212) 600-1902

Primary Logo

Back to news